News

The CEO of NeuroDerm Ltd. has been invited to discuss the company’s achievements at the Jefferies 2015 Healthcare Conference, taking place next month in New York. Oded S. Lieberman, PhD, will present a corporate overview of the company, as well as novel treatments being developed by NeuroDerm for the treatment of moderate to severe Parkinson’s disease. The…

Researchers from the University of Florida have uncovered a biomarker that reveals the progression of Parkinson’s disease in the brain. This finding opens a new path toward improved diagnosis and treatment of the degenerative disease. The interdisciplinary research team compared brain images of Parkinson’s patients with images belonging to a control group for…

Biotie Therapies has announced an agreement with the United States Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the company’s Phase 3 Parkinson’s disease study of tozadenant. The study (TOZ-PD) will evaluate both the safety and the efficacy of tozadenant in comparison to placebo in Parkinson’s patients currently…

The Michael J. Fox Foundation for Parkinson’s Research has announced that it is collaborating with The Edmond J. Safra Foundation to select four academic centers across the United States and one more in Canada to host the inaugural class of the Edmond J. Safra Fellowship in Movement Disorders. The five 2016-2018…

Amarantus BioScience Holdings (AMBS), a company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, recently announced that it has completed research in which mesencephalic-astrocyte-derived neurotrophic factor (MANF) was administered to the substantial nigra and the putamen of pigs by convection-enhanced…

According to a recent survey, there is a need for a Parkinson’s disease organization that is committed to and focused on a grassroots voice and the consolidation of resources. In response to this, “Parkinson’s People for Awareness & Unity,” an Indiegogo campaign, was recently created to raise money…

Italian pharmaceutical company Zambon S.p.A. and Newron Pharmaceuticals S.p.A. have announced plans to launch Xadago, a drug therapy for mid- to late-stage Parkinson’s disease, in Germany. The release of the treatment is the result of a partnership between the two companies, and Germany will become the first country to commercialize the drug. “The launch of…

Amarantus BioScience Holdings, a biotechnology company developing diagnostic and therapeutic products to address neurological disorders and orphan conditions, recently announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a United States Patent Application entitled, “Pharmacological Treatment of Parkinson’s Disease.” The patent will address intellectual property protection for eltoprazine, Amarantus’s lead…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF) have celebrated a new collaborative alliance at an event in which the MJFF awarded the inaugural Bachmann-Strauss Prize for Excellence in Dystonia Research. The prize was awarded for distinguished groundbreaking advancements and discoveries in the field…

The 27th annual Supercomputing Conference (SC15), formally known as The International Conference for High Performance Computing, Networking, Storage and Analysis, will be held in the Austin Convention Center at Austin, Texas from November 15-20 2015, with an attendant exhibition to be open from November 16-19. The conference, sponsored by…